8-K Announcements
6Material company update
Mar 30, 2026·SEC
Material company update
Feb 5, 2026·SEC
Material company update
Jan 27, 2026·SEC
Lexeo Therapeutics, Inc. Common Stock(LXEO)Earnings, Financials & Key Ratios
LXEO•NASDAQ
$5.82
$320M mkt cap·Price updated May 7, 2026
AboutLexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Show more
- Revenue$0
- EBITDA-$104M-55.6%
- Net Income-$98M-48.1%
- EPS (Diluted)-3.09-24.1%
- ROE-85.37%+99.6%
- ROIC-166.2%
- Debt/Equity0.08-17.1%
- Interest Coverage-927.77-177.6%
LXEO Key Insights
Lexeo Therapeutics, Inc. Common Stock (LXEO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Shares diluted 19.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
LXEO Price & Volume
Lexeo Therapeutics, Inc. Common Stock (LXEO) stock price & volume — 10-year historical chart
Loading chart...
LXEO Growth Metrics
Lexeo Therapeutics, Inc. Common Stock (LXEO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.21%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM4.26%
Return on Capital
10 Years-57.92%
5 Years-57.92%
3 Years-69.85%
Last Year-85.76%
LXEO Recent Earnings
Lexeo Therapeutics, Inc. Common Stock (LXEO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (50%)
Q2 2026Latest
Mar 30, 2026EPS
$0.27
Est $0.32
+15.6%
Revenue
—
Q4 2025
Nov 5, 2025EPS
$0.33
Est $0.48
+31.3%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.60
Est $0.64
+6.3%
Revenue
—
Q2 2025
May 12, 2025EPS
$0.99
Est $0.80
-23.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 30, 2026 | $0.27vs $0.32+15.6% | — |
| Q4 2025 | Nov 5, 2025 | $0.33vs $0.48+31.3% | — |
| Q3 2025 | Aug 14, 2025 | $0.60vs $0.64+6.3% | — |
| Q2 2025 | May 12, 2025 | $0.99vs $0.80-23.8% | — |
Based on last 12 quarters of dataView full earnings history →
LXEO Peer Comparison
Lexeo Therapeutics, Inc. Common Stock (LXEO) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCKT | 397.53M | 3.67 | -1.83 | -80.49% | 0.09 | |||
 KRYS | 8.75B | 296.70 | 43.38 | 33.94% | 53.92% | 19.25% | 0.01 | |
 SGMO | 21.54M | 0.10 | -0.21 | -67.2% | -331.28% | -8.14% | 1.34 | |
 RARE | 2.57B | 26.13 | -4.48 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.86B | 22.57 | 9.85 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 ARWR | 10.92B | 77.95 | -6389.34 | 232.58% | -48.38% | -55.47% | 0.73 |
Compare LXEO vs Peers
Lexeo Therapeutics, Inc. Common Stock (LXEO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LXEO Income Statement
Lexeo Therapeutics, Inc. Common Stock (LXEO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 518.48K | 1.66M | 654K | 0 | 0 | 0 |
| Revenue Growth % | - | 219.59% | -60.53% | -100% | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 1.04M |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 518.48K▲ 0% | 1.66M▲ 219.6% | 654K▼ 60.5% | 0▼ 100.0% | 0▲ 0% | -1.04M▲ 0% |
| Gross Margin % | 100% | 100% | 100% | - | - | - |
| Gross Profit Growth % | - | 219.59% | -60.53% | -100% | - | - |
| Operating Expenses | 5.11M | 52.29M | 61.16M | 68.51M | 105.77M | 112.48M |
| OpEx % of Revenue | 984.86% | 3155.94% | 9352.14% | - | - | - |
| Selling, General & Admin | 787.5K | 7.17M | 12M | 15.38M | 31.68M | 47.04M |
| SG&A % of Revenue | 151.89% | 432.89% | 1835.02% | - | - | - |
| Research & Development | 4.32M | 45.12M | 49.16M | 53.13M | 74.09M | 65.95M |
| R&D % of Revenue | 832.97% | 2723.05% | 7517.13% | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -510K |
| Operating Income | -4.59M▲ 0% | -50.64M▼ 1003.7% | -60.51M▼ 19.5% | -68.51M▼ 13.2% | -105.77M▼ 54.4% | -113.52M▲ 0% |
| Operating Margin % | -884.86% | -3055.94% | -9252.14% | - | - | - |
| Operating Income Growth % | - | -1003.73% | -19.5% | -13.23% | -54.37% | - |
| EBITDA | -4.59M | -50.62M | -59.36M | -66.67M | -103.76M | -111.46M |
| EBITDA Margin % | -884.86% | -3055.16% | -9077.06% | - | - | - |
| EBITDA Growth % | - | -1003.45% | -17.26% | -12.31% | -55.64% | -21.97% |
| D&A (Non-Cash Add-back) | 0 | 13K | 1.15M | 1.84M | 2M | 2.06M |
| EBIT | -4.59M | -50.62M | -59.19M | -66.19M | -98.2M | -104.81M |
| Net Interest Income | -147.15K | 15K | 1.23M | 2.66M | 7.44M | 5.21M |
| Interest Income | 0 | 15K | 1.32M | 2.87M | 7.56M | 5.34M |
| Interest Expense | 147.15K | 0 | 91K | 205K | 114K | 139K |
| Other Income/Expense | -565K | 15K | 1.23M | 2.12M | 7.43M | 8.56M |
| Pretax Income | -5.15M▲ 0% | -50.62M▼ 882.4% | -59.28M▼ 17.1% | -66.39M▼ 12.0% | -98.33M▼ 48.1% | -104.97M▲ 0% |
| Pretax Margin % | -993.83% | -3055.04% | -9063.76% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -5.15M▲ 0% | -50.62M▼ 882.4% | -59.28M▼ 17.1% | -66.39M▼ 12.0% | -98.33M▼ 48.1% | -104.97M▲ 0% |
| Net Margin % | -993.83% | -3055.04% | -9063.76% | - | - | - |
| Net Income Growth % | - | -882.42% | -17.1% | -12.01% | -48.11% | -21.21% |
| Net Income (Continuing) | -5.15M | -50.62M | -59.28M | -66.39M | -98.33M | -104.97M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.20▲ 0% | -2.01▼ 905.0% | -2.40▼ 19.4% | -2.49▼ 3.8% | -3.09▼ 24.1% | -1.72▲ 0% |
| EPS Growth % | - | -905% | -19.4% | -3.75% | -24.1% | 4.26% |
| EPS (Basic) | -0.20 | -2.01 | -2.36 | -2.49 | -3.09 | - |
| Diluted Shares Outstanding | 25.17M | 25.17M | 25.17M | 26.65M | 31.79M | 60.98M |
| Basic Shares Outstanding | 25.17M | 25.17M | 25.17M | 26.65M | 31.79M | 60.98M |
| Dividend Payout Ratio | - | - | - | - | - | - |
LXEO Balance Sheet
Lexeo Therapeutics, Inc. Common Stock (LXEO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 29.41M | 136.68M | 80.05M | 124.29M | 126.12M | 127.79M |
| Cash & Short-Term Investments | 29.37M | 135.86M | 77.33M | 121.47M | 121.52M | 41M |
| Cash Only | 29.37M | 135.86M | 77.33M | 121.47M | 35.01M | 41M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 86.5M | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 33.57K | 696K | 371K | 3K | 4.6M | 86.8M |
| Total Non-Current Assets | 2.5K | 176K | 21.26M | 15.51M | 20.82M | 16.05M |
| Property, Plant & Equipment | 0 | 174K | 13.78M | 12.26M | 10.56M | 9.41M |
| Fixed Asset Turnover | - | 9.52x | 0.05x | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 7.01M | 37.05M |
| Other Non-Current Assets | 2.5K | 2K | 7.49M | 3.25M | 3.25M | 13.41M |
| Total Assets | 29.41M▲ 0% | 136.86M▲ 365.4% | 97.08M▼ 29.1% | 139.81M▲ 44.0% | 146.94M▲ 5.1% | 143.84M▲ 0% |
| Asset Turnover | 0.02x | 0.01x | 0.01x | - | - | 0.00x |
| Asset Growth % | - | 365.36% | -29.07% | 44.02% | 5.1% | -61.51% |
| Total Current Liabilities | 697.72K | 7.45M | 14.35M | 17.24M | 22.85M | 17.27M |
| Accounts Payable | 44.32K | 3.06M | 2.68M | 3.79M | 6.42M | 4.66M |
| Days Payables Outstanding | - | - | - | - | - | 3.78K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 2.67M | 2.71M |
| Deferred Revenue (Current) | 140.38K | 46K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.03K | 961K | 2.15M | 3.36M | 4.66M | 9.9M |
| Current Ratio | 42.15x | 18.35x | 5.58x | 7.21x | 5.52x | 5.52x |
| Quick Ratio | 42.15x | 18.35x | 5.58x | 7.21x | 5.52x | 5.52x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 34.25M | 185.01M | 195.68M | 9.03M | 7.25M | 5.74M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 5.74M |
| Capital Lease Obligations | 0 | 0 | 10.65M | 9.03M | 7.25M | 20.26M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 34.25M | 185.01M | 185.03M | 0 | 0 | 0 |
| Total Liabilities | 34.95M | 192.46M | 210.03M | 26.27M | 30.1M | 23.01M |
| Total Debt | 0 | 0 | 13.48M | 11.64M | 9.92M | 8.46M |
| Net Debt | -29.37M | -135.86M | -63.85M | -109.83M | -25.09M | -32.54M |
| Debt / Equity | - | - | - | 0.10x | 0.08x | 0.08x |
| Debt / EBITDA | - | - | - | - | - | -0.08x |
| Net Debt / EBITDA | - | - | - | - | - | 0.29x |
| Interest Coverage | -31.18x | - | -664.93x | -334.21x | -927.77x | -754.06x |
| Total Equity | -5.54M▲ 0% | -55.6M▼ 904.3% | -112.95M▼ 103.1% | 113.53M▲ 200.5% | 116.84M▲ 2.9% | 120.83M▲ 0% |
| Equity Growth % | - | -904.29% | -103.15% | 200.51% | 2.91% | -78.4% |
| Book Value per Share | -0.22 | -2.21 | -4.49 | 4.26 | 3.68 | 1.98 |
| Total Shareholders' Equity | -5.54M | -55.6M | -112.95M | 113.53M | 116.84M | 120.83M |
| Common Stock | 1.6K | 1.68K | 0 | 3K | 3K | 5K |
| Retained Earnings | -5.55M | -56.17M | -115.45M | -181.84M | -280.17M | -359.21M |
| Treasury Stock | 0 | 0 | 0 | 0 | -17K | 0 |
| Accumulated OCI | 0 | -185.01M | -185.03M | 0 | -103K | 89K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
LXEO Cash Flow Statement
Lexeo Therapeutics, Inc. Common Stock (LXEO) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -3.13M | -44.18M | -54.56M | -59.5M | -81.15M | -81.15M |
| Operating CF Margin % | -604.35% | -2666.39% | -8342.51% | - | - | - |
| Operating CF Growth % | - | -1310.04% | -23.49% | -9.05% | -36.4% | -249.68% |
| Net Income | -5.15M | -50.62M | -59.28M | -66.39M | -98.33M | -104.97M |
| Depreciation & Amortization | 0 | 13K | 1.15M | 1.84M | 2M | 2.06M |
| Stock-Based Compensation | 0 | 386K | 1.78M | 3.04M | 12.47M | 12.93M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.87M | 0 | 0 | 530K | -23K | -3.31M |
| Working Capital Changes | 150.15K | 6.04M | 1.79M | 1.48M | 2.73M | -13.52M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 44.32K | 3.02M | -426K | -180K | 2.38M | -3.8M |
| Cash from Investing | 0 | -188K | -901K | -165K | -94.08M | -82.15M |
| Capital Expenditures | 0 | -188K | -672K | -115K | -481K | -384K |
| CapEx % of Revenue | - | 11.35% | 102.75% | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -229K | -50K | 0 | 0 |
| Cash from Financing | 32.38M | 150.86M | 189K | 103.79M | 88.78M | 72.93M |
| Debt Issued (Net) | 2.6M | 0 | -163K | 3.58M | -410K | -480K |
| Equity Issued (Net) | 30M | 151.06M | 20K | 100.25M | 88.69M | 80.29M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -17K | -4K |
| Other Financing | -223.59K | -203K | 332K | -35K | 491K | -6.88M |
| Net Change in Cash | 29.25M▲ 0% | 106.49M▲ 264.1% | -55.27M▼ 151.9% | 44.13M▲ 179.8% | -86.45M▼ 295.9% | -116.03M▲ 0% |
| Free Cash Flow | -3.13M▲ 0% | -44.37M▼ 1316.0% | -55.46M▼ 25.0% | -59.66M▼ 7.6% | -81.63M▼ 36.8% | -107.19M▲ 0% |
| FCF Margin % | -604.35% | -2677.73% | -8480.28% | - | - | - |
| FCF Growth % | - | -1316.04% | -25% | -7.57% | -36.83% | -59.1% |
| FCF per Share | -0.12 | -1.76 | -2.20 | -2.24 | -2.57 | -2.57 |
| FCF Conversion (FCF/Net Income) | 0.61x | 0.87x | 0.92x | 0.90x | 0.83x | 1.02x |
| Interest Paid | 0 | 0 | 77K | 176K | 127K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
LXEO Key Ratios
Lexeo Therapeutics, Inc. Common Stock (LXEO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -22855.08% | -85.37% | -90.49% |
| Return on Invested Capital (ROIC) | - | - | - | -166.2% | -166.2% |
| Gross Margin | 100% | 100% | - | - | - |
| Net Margin | -3055.04% | -9063.76% | - | - | - |
| Debt / Equity | - | - | 0.10x | 0.08x | 0.08x |
| Interest Coverage | - | -664.93x | -334.21x | -927.77x | -754.06x |
| FCF Conversion | 0.87x | 0.92x | 0.90x | 0.83x | 1.02x |
| Revenue Growth | 219.59% | -60.53% | -100% | - | - |
LXEO SEC Filings & Documents
Lexeo Therapeutics, Inc. Common Stock (LXEO) SEC filings — annual & quarterly reports (10-K, 10-Q)
LXEO Frequently Asked Questions
Lexeo Therapeutics, Inc. Common Stock (LXEO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lexeo Therapeutics, Inc. Common Stock (LXEO) grew revenue by 0.0% over the past year. Growth has been modest.
Lexeo Therapeutics, Inc. Common Stock (LXEO) reported a net loss of $105.0M for fiscal year 2024.
Dividend & Returns
Lexeo Therapeutics, Inc. Common Stock (LXEO) has a return on equity (ROE) of -85.4%. Negative ROE indicates the company is unprofitable.
Lexeo Therapeutics, Inc. Common Stock (LXEO) had negative free cash flow of $107.2M in fiscal year 2024, likely due to heavy capital investments.
Explore More LXEO
Lexeo Therapeutics, Inc. Common Stock (LXEO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates